USA flag logo/image

An Official Website of the United States Government

CELL-BASED HIGH THROUGHPUT SCREENING FOR ANTI-ANDROGENS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60015
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
CA096189
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANDROSCIENCE CORPORATION
11175 FLINTKOTE AVE., SUITE F SAN DIEGO, CA 92121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: CELL-BASED HIGH THROUGHPUT SCREENING FOR ANTI-ANDROGENS
Agency: HHS
Contract: 1R43CA096189-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by the applicant): Prostate cancer is the most frequently diagnosed cancer in American men and the second leading cause of male cancer death. Antiandrogens have been used with castration to prevent the progression of prostate cancer. However, cancer relapse often occurs within 2-3 years in patients who received this therapy. This has prompted interest in developing better antiandrogens for prostate cancer treatment. Traditional Chinese Herbal Medicines (TCHM) have been shown to block recurrent prostate cancer growth. In our preliminary study, using a newly-developed androgen receptor (AR) and androgen receptor co-activator (ARA)-mediated transactivation assay, it was found that some extracts from TCHM inhibited AR-induced gene activation, suggesting TCHM is an excellent source to search for new antiandrogen drugs. A cell-based androgen/AR activation assay developed from this study is advantageous in discovering antiandrogens that exert their inhibitory function at different stages of an androgen-induced gene activation. Performing this assay could lead to the discovery of potentially new and different antiandrogen drugs. Conventional antiandrogens only interfere with androgen and AR binding, such as HF (hydroxyflutamide) or casodex (bicalutamide). In this application we propose to develop a high throughput 96-well format AR/ARA transactivation assay using three prostate cancer cell lines: DU145, PC3 and LNCaP. In collaboration with our corporate partner, Plantaceutica Inc. (Chapel Hill, NC), a large number of extracts and compounds from TCHM that are known to possess ingredients with potential antiandrogen and androgenic activities will be screened. Compounds from TCHM extracts with effects to block wild type AR and mutant AR transactivation in all three human prostate cancer cell models will be further tested in a proliferation assay using androgen-sensitive prostate cancer, LNCaP cells to assess their biological efficacy in suppressing prostate cancer cell growth. Compounds discovered by our study with antiandrogenic or androgenic activities will have great potential to be developed into new drugs that will improve the treatment of prostate cancer patients and other androgen related disorders. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Principal Investigator:

Charles Shih
8586387230
CYSHIH@ANDROSCIENCE.COM

Business Contact:

Kathy Wartenberg
8586387230
KWARTENBERG@ANDROSCIENCE.COM
Small Business Information at Submission:

ANDROSCIENCE CORPORATION
ANDROSCIENCE CORPORATION 11175 FLINTKOTE AVE, STE F SAN DIEGO, CA 92121

EIN/Tax ID: 330913431
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No